Loading clinical trials...
Loading clinical trials...
Multiple Reaction Monitoring (MRM) Versus I 125 Radioimmunoassay (RIA) for the Quantification of Orexin-A/Hypocretin-1 Levels in Cerebrospinal Fluid: a Prospective Diagnostic Validation Study in Patients With Hypersomnolence
Conditions
Interventions
Quantitative mass spectrometry assay
Locations
1
France
University Hospital of Montpellier
Montpellier, France
Start Date
February 15, 2023
Primary Completion Date
July 30, 2025
Completion Date
October 30, 2025
Last Updated
May 29, 2024
NCT07363720
NCT05816382
NCT06952699
NCT04806620
NCT06809803
NCT06457945
Lead Sponsor
University Hospital, Montpellier
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions